Parabens (methylparaben, ethylparaben, propylparaben, butylparaben and their relatives) have been used as cosmetic preservatives since the 1920s, specifically because they're cheap, effective against a broad range of bacteria and fungi, and — compared to many alternatives — well tolerated by skin. The controversy isn't really about whether they preserve products effectively. It's about a narrower, genuinely unresolved question: do they meaningfully interfere with hormone signalling at the doses people are actually exposed to?
The weak-oestrogen finding
Parabens can bind to oestrogen receptors and produce a weak oestrogenic effect in laboratory assays — this part isn't seriously disputed.1 What's disputed is whether that weak effect, at the concentrations found in finished cosmetic products and at normal rates of skin absorption, adds up to anything biologically meaningful in a human body that also produces its own, vastly more potent oestrogen naturally.
Longer-chain parabens (propyl-, butyl-, isopropyl-, isobutyl-) show stronger oestrogenic activity in lab assays than shorter-chain ones (methyl-, ethyl-), which is the main reason regulatory decisions have treated them differently rather than banning the whole category.
The breast tissue study, and why it's more cautious than the headlines
In 2004, a UK study by Philippa Darbre and colleagues reported finding intact, unmetabolised parabens in a small sample of human breast tumour tissue.2 This finding is widely cited as evidence parabens cause breast cancer — but the study itself didn't establish that, and said so explicitly. It had no control group of healthy (non-tumour) breast tissue for comparison, couldn't determine the source of the parabens (cosmetics are only one of several possible routes), and didn't demonstrate that the parabens caused the tumours rather than simply being present in the body generally, as they are in most people who use any cosmetic products. The authors themselves were careful to frame it as detection, not causation — a distinction that got lost in a lot of the coverage that followed.
Where regulators landed
The EU's Scientific Committee on Consumer Safety reviewed the evidence and concluded that methylparaben and ethylparaben are safe at the concentrations typically used in cosmetics. For propylparaben and butylparaben, the committee set stricter concentration limits as a precaution given the uncertainty, rather than banning them outright. Five longer-chain parabens — isopropylparaben, isobutylparaben, phenylparaben, benzylparaben and pentylparaben — were banned in the EU in 2014 specifically because there wasn't enough safety data to assess them confidently, not because they'd been shown to cause harm. That's a meaningful distinction: it's a "we don't have enough evidence either way" decision, not a "we found proof of danger" one.
Where that leaves us
This is a genuinely contested area, and we're not going to pretend the science has settled on "parabens are dangerous." It hasn't. What it has settled on is that parabens are weak endocrine modulators with still-uncertain real-world significance, that regulators have responded to that uncertainty by restricting the higher-activity, lower-data variants rather than the whole category, and that a meaningful number of people would simply prefer to avoid the uncertainty altogether given that effective, well-tolerated non-paraben preservation options exist.
That's the position we formulate from: not that paraben-containing products are unsafe, but that given a genuine choice and no meaningful downside to avoiding them, we'd rather not add an ingredient with an open question mark next to it.